TrialCancer chemotherapy and pharmacology2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
Heather A Wakelee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this paperpooled itcites it